(2S,3S,4R,5R)-3-amino-5-[6-[(2,5-dichlorophenyl)methylamino]purin-9-yl]-4-hydroxy-N-methyloxolane-2-carboxamide | 457612-59-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S,4R,5R)-3-amino-5-[6-[(2,5-dichlorophenyl)methylamino]purin-9-yl]-4-hydroxy-N-methyloxolane-2-carboxamide
• CAS: 457612-59-8
• 化学式: C₁₈H₁₉Cl₂N₇O₃
• 分子量: 452.3
• InChiKey: WFRYPIJMCFQCGT-MHMFGPJMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2S,3S,4R,5R)-3-amino-5-[6-[(2,5-dichlorophenyl)methylamino]purin-9-yl]-4-hydroxy-N-methyloxolane-2-carboxamide 、 Diethyl <(4-cyano-1-naphthyl)methyl>phosphonate 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 以14%的产率得到1-[1-(4-cyclohexylphenyl)-4-piperidyl]-4-[(4-cyano-1-naphthyl)methylene]-piperidine
  参考文献：
  名称：

  Stepwise versus Direct Long-Range Charge Separation in Molecular Triads

  摘要：

  Trifunctional electron donor-donor-acceptor molecules are described in which photoinduced charge separation, D-2-D-1-A* --> D-2-D-1(+)-A(-), is followed by a charge migration step D-2-D-1(+)-A(-) (CS1) --> D-2(+)-D-1-A- (CS2), leading to a relatively long-lived charge-separated state. The rate of the charge migration process could be determined in a range of solvents of low polarity. In benzene and dioxane, reversibility of the process allowed the determination of the free energy difference between CS1 and CS2. The relative energy of the CS2 state is much lower than expected from simple electrostatic models. An increase of the charge migration rate was found with increasing solvent polarity within a series of alkyl ethers or alkyl acetates. However, an apparent preferential stabilization of the CS1 state in acetates relative to ethers leads to discontinuities in the solvatochromic shift behavior of the CT fluorescence from the CS1 state, and in the increase of the charge migration rate as a function of dielectric constant. In a reference compound lacking the intermediate redox unit, direct long-range charge separation yielding a D-2(+)-bridge-A(-) charge-separated state can occur, but the yield is significantly lower than in the triads.

  DOI：

  10.1021/ja983716r
• 作为产物：
  描述：

  1,5-二氯-3-戊酮 在 盐酸羟胺 、 sodium carbonate 、 potassium carbonate 、 红铝 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 为溶剂， 生成 (2S,3S,4R,5R)-3-amino-5-[6-[(2,5-dichlorophenyl)methylamino]purin-9-yl]-4-hydroxy-N-methyloxolane-2-carboxamide
  参考文献：
  名称：

  Stepwise versus Direct Long-Range Charge Separation in Molecular Triads

  摘要：

  Trifunctional electron donor-donor-acceptor molecules are described in which photoinduced charge separation, D-2-D-1-A* --> D-2-D-1(+)-A(-), is followed by a charge migration step D-2-D-1(+)-A(-) (CS1) --> D-2(+)-D-1-A- (CS2), leading to a relatively long-lived charge-separated state. The rate of the charge migration process could be determined in a range of solvents of low polarity. In benzene and dioxane, reversibility of the process allowed the determination of the free energy difference between CS1 and CS2. The relative energy of the CS2 state is much lower than expected from simple electrostatic models. An increase of the charge migration rate was found with increasing solvent polarity within a series of alkyl ethers or alkyl acetates. However, an apparent preferential stabilization of the CS1 state in acetates relative to ethers leads to discontinuities in the solvatochromic shift behavior of the CT fluorescence from the CS1 state, and in the increase of the charge migration rate as a function of dielectric constant. In a reference compound lacking the intermediate redox unit, direct long-range charge separation yielding a D-2(+)-bridge-A(-) charge-separated state can occur, but the yield is significantly lower than in the triads.

  DOI：

  10.1021/ja983716r

文献信息

• [EN] COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT D'UNE DÉPENDANCE ET DE TROUBLES ASSOCIÉS
  申请人：ASTROCYTE PHARMACEUTICALS INC

  公开号：WO2019157317A1

  公开（公告）日：2019-08-15

  The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example an addiction or compulsive disorder.

  本发明涉及化合物及其治疗某些疾病和症状的方法，例如成瘾或强迫性障碍。
• Compounds for the treatment of ischemia
  申请人：——

  公开号：US20030055021A1

  公开（公告）日：2003-03-20

  A 3 agonists having Formula I are described herein as well as methods of using such A 3 agonists and pharmaceutical compositions containing such A 3 agonists. 1 The A 3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.

  本文描述了具有I式的A3受体激动剂，以及使用这种A3受体激动剂的方法和含有这种A3受体激动剂的药物组合物。这些A3受体激动剂对于减少由组织缺血或低氧引起的组织损伤是有用的。
• Purine derivatives for the treatment of ischemia
  申请人：Pfizer Products Inc.

  公开号：EP1241176A1

  公开（公告）日：2002-09-18

  A3 agonists having Formula I are described herein as well as methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.

  本文描述了具有式 I 的 A3 激动剂以及使用这种 A3 激动剂的方法和含有这种 A3 激动剂的药物组合物。 A3 激动剂可用于减少组织缺血或缺氧造成的组织损伤。
• Compounds and methods for treating neurological and cardiovascular conditions
  申请人：Astrocyte Pharmaceuticals, Inc.

  公开号：US10265338B2

  公开（公告）日：2019-04-23

  The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

  本发明涉及用于治疗某些疾病和病症（例如脑损伤，如中风或脑外伤）的化合物及其使用方法。
• A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION
  申请人：Oradin Pharmaceutical Ltd.

  公开号：EP2456419A1

  公开（公告）日：2012-05-30